Morgan Stanley Aptinyx Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.12 - $0.69 $11,617 - $66,798	96,809 Added 1221.26%	104,736 $12,000
Q4 2022 Feb 14, 2023	SELL	$0.23 - $0.34 $0 - $0	-1 Reduced 0.01%	7,927 $2,000
Q3 2022 Nov 14, 2022	SELL	$0.35 - $0.72 $20,969 - $43,137	-59,913 Reduced 88.31%	7,928 $3,000
Q2 2022 Oct 27, 2022	SELL	$0.38 - $2.58 $6,343 - $43,067	-16,693 Reduced 19.75%	67,841 $38,000
Q2 2022 Aug 15, 2022	SELL	$0.38 - $2.58 $6,343 - $43,067	-16,693 Reduced 19.75%	67,841 $38,000
Q1 2022 Oct 27, 2022	BUY	$2.27 - $3.62 $37,893 - $60,428	16,693 Added 24.61%	84,534 $192,000
Q1 2022 May 13, 2022	SELL	$2.27 - $3.62 $281,806 - $449,401	-124,144 Reduced 59.49%	84,534 $192,000
Q4 2021 Feb 14, 2022	SELL	$2.11 - $3.0 $22,707 - $32,286	-10,762 Reduced 4.9%	208,678 $556,000
Q3 2021 Nov 15, 2021	BUY	$2.21 - $2.89 $484,962 - $634,181	219,440 New	219,440 $514,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.